Compare Stocks → Elon to Transform U.S. Economy? (From Porter & Company) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:ALURNASDAQ:DCTHNASDAQ:STIMNASDAQ:TELA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALURAllurion Technologies$2.30+4.5%$2.32$1.56▼$9.00$110.06M-0.13753,835 shs39,233 shsDCTHDelcath Systems$5.56+2.2%$4.64$2.25▼$7.99$154.46M0.55223,058 shs76,812 shsSTIMNeuronetics$3.81+8.9%$3.95$1.03▼$5.07$114.22M2.5172,357 shs41,757 shsTELATELA Bio$4.72+1.9%$5.45$4.23▼$11.26$116.35M1136,231 shs30,331 shs10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALURAllurion Technologies-6.38%+18.28%+14.58%-25.17%+219,999,900.00%DCTHDelcath Systems+0.74%+3.42%+15.74%+15.62%-6.53%STIMNeuronetics-1.55%-0.57%-22.91%+3.55%+55.56%TELATELA Bio0.00%+5.47%-12.64%-33.29%-51.26%Automatic Income (from home) (Ad)For over 22 years, Wall Street elites have kept this little-known "income hack" from everyday investors… 6 simple clicks have set up HUGE payouts for "in-the-know" investors… Delivering them passive income 365 days a year. Just click here now to watch my presentation for free.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALURAllurion Technologies2.2881 of 5 stars3.53.00.00.03.00.80.6DCTHDelcath Systems4.0719 of 5 stars3.55.00.00.04.34.20.6STIMNeuronetics2.8459 of 5 stars3.35.00.00.02.61.70.6TELATELA Bio1.1862 of 5 stars3.52.00.00.00.01.70.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALURAllurion Technologies3.00Buy$5.00117.39% UpsideDCTHDelcath Systems3.00Buy$18.50232.73% UpsideSTIMNeuronetics2.50Moderate Buy$8.00109.97% UpsideTELATELA Bio3.00Buy$13.67189.55% UpsideCurrent Analyst RatingsLatest DCTH, ALUR, STIM, and TELA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/4/2024ALURAllurion TechnologiesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.003/27/2024DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.003/26/2024STIMNeuroneticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Perform3/22/2024TELATELA BioJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$15.003/22/2024TELATELA BioPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$15.00 ➝ $12.003/6/2024STIMNeuroneticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.00 ➝ $8.002/9/2024ALURAllurion TechnologiesJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$5.00(Data available from 5/3/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALURAllurion Technologies$53.47M2.06N/AN/A($1.48) per share-1.55DCTHDelcath Systems$2.07M74.62N/AN/A$0.72 per share7.72STIMNeuronetics$71.35M1.60N/AN/A$1.18 per share3.23TELATELA Bio$58.45M1.99N/AN/A$0.77 per share6.13Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALURAllurion Technologies-$80.61MN/A0.00N/AN/AN/AN/A-97.97%5/14/2024 (Confirmed)DCTHDelcath Systems-$47.68M-$2.97N/AN/AN/A-2,308.86%-563.60%-111.13%5/27/2024 (Estimated)STIMNeuronetics-$30.19M-$1.07N/AN/AN/A-42.31%-72.76%-29.25%5/7/2024 (Confirmed)TELATELA Bio-$46.66M-$2.07N/AN/AN/A-79.83%-201.62%-58.60%5/9/2024 (Confirmed)Latest DCTH, ALUR, STIM, and TELA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024N/AALURAllurion TechnologiesN/AN/AN/AN/AN/AN/A 5/9/2024N/ATELATELA Bio-$0.48N/A+$0.48N/AN/AN/A 5/7/2024N/ASTIMNeuronetics-$0.33N/A+$0.33N/AN/AN/A 3/26/2024Q4 23DCTHDelcath Systems-$0.67-$0.48+$0.19-$0.48$0.48 million$0.54 million 3/21/2024Q4 2023ALURAllurion Technologies-$0.51-$0.63-$0.12-$0.86$8.20 million$8.24 million3/21/2024Q4 2023TELATELA Bio-$0.44-$0.53-$0.09-$0.53$16.65 million$17.00 million3/5/202412/31/2023STIMNeuronetics-$0.26-$0.19+$0.07-$0.19$19.73 million$20.31 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALURAllurion TechnologiesN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/ASTIMNeuroneticsN/AN/AN/AN/AN/ATELATELA BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALURAllurion TechnologiesN/A0.990.90DCTHDelcath SystemsN/A2.262.06STIMNeuronetics1.734.734.33TELATELA Bio2.154.233.45OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALURAllurion Technologies21.39%DCTHDelcath Systems61.12%STIMNeuronetics53.59%TELATELA Bio94.35%Insider OwnershipCompanyInsider OwnershipALURAllurion Technologies20.00%DCTHDelcath Systems17.94%STIMNeuronetics9.80%TELATELA Bio6.00%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableALURAllurion Technologies50147.85 million38.28 millionOptionableDCTHDelcath Systems7627.78 million22.80 millionOptionableSTIMNeuronetics20329.98 million27.04 millionOptionableTELATELA Bio22724.65 million23.18 millionOptionableDCTH, ALUR, STIM, and TELA HeadlinesSourceHeadlineScoPo’s Powerplays: ASX Health stocks rise in big week of quarterly reportsmsn.com - May 3 at 2:38 AMTELA Bio (TELA) Scheduled to Post Quarterly Earnings on Thursdayamericanbankingnews.com - May 2 at 3:50 AMTELA Bio to Announce First Quarter 2024 Financial Resultsglobenewswire.com - April 25 at 7:00 AMTELA Bio Launches Innovative Hernia Repair Device in the U.S. Marketmsn.com - April 17 at 9:16 AMTELA Bio launches OviTex IHR for inguinal hernia repair in USmsn.com - April 16 at 5:32 PMTELA Bio announces US launch OviTex IHR for use in laparoscopic and robotic-assisted inguinal hernia repairpharmabiz.com - April 16 at 7:29 AMTELA Bio Announces U.S. Commercial Launch of Robotic-Compatible OviTex® IHR – Addressing the Need for a More Natural Repair in Inguinal Hernia Proceduresglobenewswire.com - April 15 at 7:00 AMMDXG: Legal Avenuesfinance.yahoo.com - April 11 at 1:10 PMTELA Bio Appoints Esteemed Surgeon Dr. Howard N. Langstein as Vice President of Medical Affairsmsn.com - April 10 at 6:58 AMTELA Bio, Inc.: TELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategyfinanznachrichten.de - April 8 at 4:17 PMTELA Bio Welcomes Acclaimed Surgeon as Vice President of Medical Affairs and Surgeon Strategyglobenewswire.com - April 8 at 7:00 AMTELA Bio Stands Tall With Consistent Growth, Novel Products, and a Promising Revenue Projection for 2024msn.com - March 25 at 8:23 AMAnalysts Are Updating Their TELA Bio, Inc. (NASDAQ:TELA) Estimates After Its Full-Year Resultsfinance.yahoo.com - March 24 at 5:22 PMTELA Bio, Inc. (TELA) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 23 at 11:14 PMTELA Bio Full Year 2023 Earnings: US$2.04 loss per share (vs US$2.72 loss in FY 2022)finance.yahoo.com - March 23 at 8:39 AMTELA Bio Announces U.S. Commercial Launch of LIQUIFIX(TM) - the Only FDA-Approved Liquid Adhesive for Internal Use in Hernia Surgerystockhouse.com - March 22 at 5:36 PMTELA Bio, Inc. (NASDAQ:TELA) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 22 at 5:36 PMQ4 2023 TELA Bio Inc Earnings Callfinance.yahoo.com - March 22 at 7:36 AMRecap: TELA Bio Q4 Earningsbenzinga.com - March 21 at 9:14 PMTELA Stock Earnings: TELA Bio Misses EPS, Beats Revenue for Q4 2023msn.com - March 21 at 9:14 PMTELA Bio Inc Reports Robust Revenue Growth in Q4 and Full Year 2023finance.yahoo.com - March 21 at 9:14 PMTELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimateszacks.com - March 21 at 6:31 PMStrategic Divestiture and Innovative Product Launch Fuel Buy Rating for TELA Biomarkets.businessinsider.com - March 21 at 4:13 PMTELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Resultsfinance.yahoo.com - March 21 at 4:13 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Stocks Leading the U.S. Agriculture ComebackApril 26, 2024 10:10 AMView 3 Stocks Leading the U.S. Agriculture ComebackHow to Use Put Debit Spreads to Profit From Falling Stocks April 26, 2024 9:30 AMView How to Use Put Debit Spreads to Profit From Falling Stocks Lockheed Martin Stock Aims for a Fresh All-Time HighApril 23, 2024 9:59 AMView Lockheed Martin Stock Aims for a Fresh All-Time HighMcDonald’s Trend Following Signal is an Opportunity TodayApril 30, 2024 9:45 AMView McDonald’s Trend Following Signal is an Opportunity TodayIBM Sings the Blues on Mixed Pockets of Strength May 1, 2024 7:00 AMView IBM Sings the Blues on Mixed Pockets of Strength All Headlines Company DescriptionsAllurion TechnologiesNYSE:ALURAllurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.Delcath SystemsNASDAQ:DCTHDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.NeuroneticsNASDAQ:STIMNeuronetics, Inc., a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder. Its NeuroStar Advanced Therapy System uses transcranial magnetic stimulation to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company sells its products through its sales and customer support team to psychiatrists. The company was incorporated in 2001 and is headquartered in Malvern, Pennsylvania.TELA BioNASDAQ:TELATELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.